Coronary Artery Disease
📧 Sign up to get email alerts when something new happens for Coronary Artery Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-06-02Clinical Trial Update: Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD [Phase 2]
Phase 2 clinical trial evaluating XTR004 as an 18F-labeled PET tracer for diagnosing known or suspected coronary artery disease has complete…
-
CLINICAL_TRIALS trial_result · 2023-06-02Clinical Trial Update: Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease [Phase 2, Phase 3]
A clinical trial update exploring body weight–adjusted clopidogrel treatment in coronary artery disease patients, spanning Phase 2 and Phase…
-
FDA approval · 2023-05-23FDA Approved: REGADENOSON — Original Application (Baxter Healthcare Corporation)
FDA approved Regadenoson (REGADENOSON) as a pharmacologic stress agent for myocardial perfusion imaging in adults unable to perform exercise…
-
CLINICAL_TRIALS trial_result · 2023-05-16Clinical Trial Update: PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment [Phase 4]
Phase 4 trial updating the pharmacodynamics and pharmacokinetics of switching between cangrelor and ticagrelor after ticagrelor pretreatment…
-
FDA approval · 2023-05-12FDA Approved: AMMONIA N 13 — Supplemental Application (SOFIE Co. dba SOFIE)
FDA approved a supplemental application for Ammonia N-13 (AMMONIA N-13) from SOFIE Co. dba SOFIE, updating its regulatory approval. This app…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-05-03Clinical Trial Update: Effect of Evolocumab on Coronary Plaque Characteristics [Phase 4]
Phase 4 trial update evaluating evolocumab's effect on coronary plaque characteristics in coronary artery disease patients; results posted.
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Short-Term Exposure to Lipophilic Anti-proliferative Drugs Delivered by Angiographic Contrast Media [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating short-term exposure to lipophilic anti-proliferative drugs delivered via angiographic contrast media in …
-
CLINICAL_TRIALS trial_result · 2023-04-26Clinical Trial Update: Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease [Phase 4]
A Phase 4 clinical trial update evaluating switching from DAPT to dual pathway inhibition with low-dose rivaroxaban in addition to aspirin f…
-
CLINICAL_TRIALS trial_result · 2023-04-26Clinical Trial Update: De-escalation of Ticagrelor in Post PPCI [Phase 1, Phase 2]
A clinical trial update on de-escalation of ticagrelor after primary percutaneous coronary intervention, spanning Phase 1 and Phase 2.
-
FDA approval · 2023-04-25FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for atorvastatin calcium by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2023-04-21FDA Approved: TICAGRELOR — Original Application (Ascend Laboratories, LLC)
FDA approved Ticagrelor under an Original Application by Ascend Laboratories, LLC. The approval supports its use as an antiplatelet therapy …
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole) [Phase 4]
Phase 4 trial update evaluating efficacy and safety of Lansoprazole for patients with Coronary Artery Disease.
-
CLINICAL_TRIALS trial_result · 2023-04-14Clinical Trial Update: Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin" [Phase 4]
Phase 4 safety trial comparing ticagrelor plus warfarin versus clopidogrel plus aspirin plus warfarin in patients with atrial fibrillation a…
-
FDA approval · 2023-04-12FDA Approved: PRASUGREL — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for the generic prasugrel from Accord Healthcare Inc., finalizing a regulatory action under the ANDA…
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease [Phase 3]
Phase 3 trial updating on the effect of atorvastatin on fractional flow reserve in patients with coronary artery disease.
-
CLINICAL_TRIALS trial_result · 2023-04-04Clinical Trial Update: The Randomized OPTIMAL-ACT Trial [Phase 2]
A Phase 2 randomized trial (OPTIMAL-ACT) completed with results posted in 2023, evaluating treatment in coronary artery disease and ischemic…
-
FDA approval · 2023-04-04FDA Approved: REGADENOSON — Original Application (Mylan Institutional LLC)
FDA approved the original ANDA for Regadenoson from Mylan Institutional LLC, enabling a generic version of the vasodilator used in pharmacol…
-
CLINICAL_TRIALS trial_result · 2023-04-03Clinical Trial Update: Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease [Phase 2]
Phase 2 trial update on dose finding and safety of RVX000222 in subjects with stable coronary artery disease.
-
CLINICAL_TRIALS trial_result · 2023-03-22Clinical Trial Update: Colchicine Protective Effect in Patients Undergoing Percutaneous Coronary Intervention (COLCHICINE-PROTECT) [Phase 3]
Phase 3 trial update on colchicine for protection in patients undergoing percutaneous coronary intervention (COLCHICINE-PROTECT) evaluating …
-
FDA approval · 2023-03-20FDA Approved: PRAVASTATIN SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Pravastatin Sodium from Aurobindo Pharma Limited, confirming continued approval of this generic …
-
CLINICAL_TRIALS trial_result · 2023-03-13Clinical Trial Update: Study With Aminophylline to Attenuate of the Side Effects of Regadenoson [Phase 4]
Phase 4 clinical trial evaluating aminophylline to reduce side effects of regadenoson (Lexiscan) in patients undergoing nuclear stress tests…
-
CLINICAL_TRIALS withdrawal · 2023-03-13Clinical Trial Update: Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries [Phase 4]
Phase 4 trial evaluating ranolazine for myocardial ischemia in patients with chronic total occlusions was withdrawn.
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery [Phase 4]
Phase 4 clinical trial assessing the effect of dapagliflozin on diabetic endothelial dysfunction in the brachial artery.
-
FDA approval · 2023-03-08FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Cipla USA Inc.,)
The FDA approved Cipla USA Inc.'s supplemental application for atorvastatin calcium (generic atorvastatin calcium) under an ANDA.
-
CLINICAL_TRIALS withdrawal · 2023-02-28Clinical Trial Update: Retrograde Autologous Priming and Mannitol for Reducing Hemodilution in Cardiac Surgery [Phase 3]
A Phase 3 trial evaluating retrograde autologous priming and mannitol to reduce hemodilution in cardiac surgery has been withdrawn.